Maelor plc, the specialist critical care pharmaceuticals and devices

Volplex A 4% solution of succinylated gelatin used in operating theatres and wards in patients who require fluid replacement.
OptiFlo UK brand of a range of catheter irrigation solutions.
ContiSol international brand of a range of catheter irrigation solutions.

Development products

Micelle nanotechnology - A drug delivery system which enables insoluble active pharmaceuticals to be solubilised.
Lead development products in this area relate to:
* Interstitial cystitis and chronic pelvic pain (Plethora Solutions)
* Wound care
* Anaesthesiology

Operational highlights announced 1 June 2006

Licensing agreement with Plethora Solutions plc for micelle nanotechnology drug delivery system for use in the treatment of interstitial cystitis and painful bladder syndrome
Volplex UK rights re-acquired and product re-launched successfully. In-market sales for the second half of the year up 35% compared to the first half compared to the first half
OptiFlo UK in-market sales grow by 32% over the previous year
Jump 17%
http://www.maelor.plc.uk

10 May 2007 - Acquisition of Acorus Therapeutics Ltd completed

24 Feb 2004 - signed a major contract for the distribution of
its plasma substitute product,Volplex, in China. The agreement with Helicon Group
Pty Ltd will lead to Volplex being marketed and distributed in China through a network
of sales offices. Helicon is also charged with the regulatory submission, which should
be completed in 2004.

Volplex (succinylated gelatin) is given as an intravenous infusion to substitute
for blood volume lost by patients suffering from the effects of trauma, surgery
or certain medical conditions which result in hypovolaemia (lower than normal
blood volume).

Volplex has expanded its international franchise over the last few months,
gaining regulatory approval in Argentina in December 2003 where it will shortly
be launched. Maelor has established partners in South Africa and Bangladesh
(where regulatory applications have already been submitted) and also in
Australia in preparation for future launches in those markets.

looks like a nice little earner eh 'enry!

Anyone else in MLR ?

This from yesterday's Peter Shearlocks Small Cap Stock Picks

Transforming deal for Maelor

I tipped critical care products business Maelor last September (at 6.5p) for one reason only: its management had form for building a big pharma business from scratch. That faith appears to have been well placed. Maelor has now achieved a transforming deal with the acquisition of Acorus Therapeutics for up to 13 million. Acorus is in similar areas of neurology and critical care with products that have either been launched on the market or are at a late stage in their development therefore representing low-risk investments.

The deal transforms Maelors profit and loss account. In a trading statement on Thursday it said the final quarter of the year had sustained the upturn noted in the half-year statement and losses would be significantly below expectations. The blood plasma substitute Volplex is clearly still gaining market share. Together with Acorus, which is highly profitable, it looks as if the enlarged Maelor should make a profit of somewhere well over 1 million this year.

To help fund the deal, Maelor placed 80 million new shares at 10p on Thursday, lifting the number of shares in issue to 125 million. With the shares trading at 13.25p after the deal, that puts a value of 16.6 million on the company. There is clearly still a fair amount of upside. Continue to hold. I am a shareholder in Maelor.

After today's EGM I would expect to see some good press over the weekend as this appears to be a star in the making.

Now well in profit after the reverse takeover and with an easily manageable debt and good income flow this should be an interesting, and profitable ride, for the asute punter.

been in for a while now at 11pish so looking fwd to good times

I think that they will soon begin to roll!

Interesting. I am a shareholder in Plethora (PLE), although becoming increasingly disturbed by the failure of the company to produce the big deal for their PE product that was causing so much excitement a while back.

Here's a chart for MLR:

I bought into PLE in October '05 and sold for my Christmas box the same year. I think it has a little further to fall still and its on my watch list.

Meanwhile I expect MLR to rocket no exaggeration I mean rocket. But dont follow me, look at it yourselves.

Just out of interest and for those who have not seem this:-

Maelor plc

Maelor and Plethora Solutions enter into a licensing agreement for micelle nanotechnology
June 1st 2006 - Maelor Pharmaceuticals PLC (Maelor; AIM:MLR), the specialist critical care company, and Plethora Solutions Holdings PLC (Plethora or the Company, AIM : PLE), a UK-based speciality pharmaceutical company, are pleased to announce that Maelor has granted Plethora a licence to Maelors micelle nanotechnology delivery system.

Under the terms of the agreement, Maelor will provide Plethora with a worldwide, exclusive licence to Maelors micelle formulation nanotechnology, for application in Plethoras PSD597 programme for the treatment of interstitial cystitis and painful bladder syndrome (IC/PBS).

Plethora will be responsible for product development and the licence agreement is based upon an upfront payment, development and sales milestones and royalties to Maelor.

Micelle nanotechnology entraps drug compounds inside minute particles built up from polymers. This formulation technique can potentially deliver effective concentrations of drugs which would otherwise be insoluble in aqueous solution. The micelles may also protect the entrapped drug from hydrolysis by enzymes or protect the drug from extreme pH environments and thus enable more drug to be delivered to its site of action.

Plethora has already completed clinical pilot studies which indicated that its proprietary treatment, PSD597, can result in symptomatic relief from IC/PBS. Plethora recently announced that it had initiated a Phase II, double-blind, placebo-controlled clinical study in up to 20 centres in the US and Canada, with preliminary results anticipated at towards the end of 2006. In this study, PSD597 is being delivered locally into the bladder in a procedure conducted in an out-patient clinic. Following successful completion of this study, the micelle technology will be incorporated into the next stage of development and may open up the potential for patients to self administer treatments for interstitial cystitis.
IC/PBS is a condition characterised by chronic pelvic pain and afflicts up to two million women in the United States and Europe. The causes of IC/PBS are unknown and the few available approved treatments fail to bring about immediate and long-lasting symptomatic relief.

Maelor plc

Tim Wright, Chief Executive Officer of Maelor, commented:
As a specialist urology company with expertise in the clinical development of an IC/PBS treatment, Plethora is ideally placed to develop an effective and convenient micelle-based product for this debilitating condition and we are pleased to build upon their proprietary position in this area by providing access to our micelle nanotechnology.

Steven Powell, Chief Executive Officer of Plethora, commented:
Maelors micelle delivery technology is an ideal enhancement for this product, potentially broadening the patient population for this much needed treatment which has unique benefits for IC/PBS sufferer.

Enquiries:
Maelor plc
Tim Wright, CEO Tel: 01978 810153
Financial Dynamics
Ben Atwell/John Gilbert Tel: 020 7831 3113
Plethora Solutions
Steven Powell
Tel : 0207 269 8630
Buchanan Communications
Isabel Podda
Tel : 0207 466 5000

Notes to Editors:
A
bout Maelor:
Maelor plc is a specialist critical care pharmaceuticals and devices company. The company commercialises its critical care portfolio directly in the UK and commercialises early stage technology and non-core products through effective relationships with partners. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:MLR) Further information is available at www.maelor.plc.uk

About Plethora:
Plethora is focused on the development of products for the treatment of urological disease. The Company has products in clinical development for the treatment of overactive bladder, benign prostatic hyperplasia, stress urinary incontinence, interstitial cystitis and premature ejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based speciality sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE) Further information is available at www.plethorasolutions.co.uk

And this one----
RNS Number:4720U Maelor PLC 05 April 2007

5 April 2007


Maelor plc ("Maelor" or the "Company")
Pre-Close Statement and Trading update


The Board of Maelor plc (AIM:MLR), the specialist critical care company is pleased to announce that it expects the outcome for the full year to 31st March 2007 to be ahead of current market expectations.

The positive trading highlighted at the Company's Interim Results on 2nd November 2006 has been sustained into the last quarter of the financial year and the Board anticipates a significant reduction in losses for the second half of the financial year. The sales growth of Volplex, a plasma substitute product, the commercialisation of which has been taken in-house, has continued, driven by active promotion and successful tendering for regional contracts. Sales of catheter flushing devices also continue to progress well.

The Company is actively building its specialist critical care portfolio having recently further added to its "specials" portfolio a fluid and volume replacement product as well as AquiHex, a product that the Company has developed, for use in hospital infection control. In parallel, late stage development of its complementary plasma substitute product, ISOplex, is progressing to schedule with approval still targeted for late 2008.

Commenting on the Company's performance Tim Wright CEO said:

"We are very pleased with the progress that Maelor has made since the strategic review in June 2006. In line with our new strategy the business is now focused, stabilised and well positioned for rapid organic and acquisitive growth. The acquisition of Acorus announced separately today represents a further step in our strategy to establish a significant business in hospital specialist medicine"


Ends -
For further information, call:

Tim Wright, Maelor plc - 01244 625150

Billy Clegg/Edward Westropp, Financial Dynamics - 020 7831 3113

Matthew Hall, Noble & Company - 020 7763 2200


This information is provided by RNS
The company news service from the London Stock Exchange

information.


Maelor First Day of Dealings


RNS Number:1874W
Maelor PLC
08 May 2007

8 May 2007




Maelor plc ("Maelor" or the "Company")

Re-Admission, Conditional Placing and Acquisition



The Board of Maelor plc (AIM: MLR), the specialist critical care company, is
pleased to announce that it has conditionally raised #8 million through a
placing of 80,000,000 new ordinary shares of 10p (the "Placing") by Noble &
Company Limited, Maelor's nominated adviser and broker.


Geoff McMillan, Non-Executive Chairman, Tim Wright, Chief Executive Officer,
Nigel Goldsmith, Finance Director, Ann Hardy, Executive Director and John
Gregory, Non-Executive Director have all participated in the Placing.


First Admission and the commencement of dealings in relation to the 70,005,833
Existing Ordinary Shares and New VCT/EIS Shares will take place today. It is
expected that Second Admission and the commencement of dealings in relation to
the 44,275,000 Protected VCT Shares and Non-VCT Shares will occur at 8am on 9
May 2007 and that Third Admission and commencement of dealings in relation to
10,000,000 Consideration Shares will occur at 8am on 10 May 2007. It is expected
that completion of the acquisition of Acorus Therapeutics Limited will occur
immediately following Third Admission.


Following completion of the acquisition of Acorus Therapeutics Limited, the
Company will have 124,280,833 ordinary shares of 10p in issue.


Tim Wright, CEO of Maelor said:


"The acquisition of Acorus is a transforming transaction for Maelor, creating a
strong, profitable business with positive cash flow. The integration risks,
costs and distractions are minimal due to the virtual nature of Acorus and the
combined product portfolios offer a high degree of synergy in terms of customer
base and distribution channels. We now have a product portfolio and pipeline
capable of delivering strong future growth."


- Ends -

MLR Bid: 11p Offer: 12p Change: -0.75

yep I must admitt today's figure have beten me. All good news more buys then sells nd the price is marked down.

To me this new deal is like the flotation of a new company and on the figures the price should be more than it is now.

Perheps the old ghosts are still haunting in the minds of old investors, some of whom have been stuck in this one at over 1.60 pounds for years and are sick, sick, sick that Appleby took so much out of the company when leaving, after costing it so much--who knows?

Obviously I dont but I stood by my words and bought today.

But this certainly appears to be an unloved stock---and thoughts please guys.

Good luck all in your endevours to be rich-

hi David .... this stock is far too small to appeal to me, and the chart probably has limited value ..... however, for what it is worth, i paste it below ...... neither 25 nor 50 dma have provided the support one might have hoped, but given that they are now running contangently(?) that may well prove a stubborn resistance as and when sp recovers

Thanks Cynic thats exaclty what has me beat on this one, its doing the opposite to what it should.

Nornally I am not this far out as I love recovery situtations and do well out of them.

I have evey confidence that this will be a whole different ball game in a few months time, but this kind of trading on such good news is difficult to follow.

Thanks again for you input and good luck with your investments.

should perhaps have added that rsi is heavily o'sold and past record indicates it should at least bounce shortly

Would agree with that especially on this news----------Thanks again best wishes.

8 May 2007


Maelor plc ("Maelor" or the "Company")



Director dealings



On 8 May 2007 the Company received notification of the following share purchases
of its 10p Ordinary Shares by Directors:


Name Number of shares purchased Purchase price Total holding at the date of this announcement
Number of ordinary shares % of issued share capital

Geoff McMillan 350,000 10p 850,000 0.68%
Tim Wright 550,000 10p 1,000,000 0.80%
Nigel Goldsmith 550,000 10p 850,000 0.68%
Ann Hardy 100,000 10p 110,000 0.09%
John Gregory 200,000 10p 219,211 0.18%



On 8 May 2007 the Company granted the following share options to the Directors:


Name Number of options Exercise price Date from which options exercisable Expiry date

Geoff McMillan 310,702 10p 8 May 2010 8 May 2017
Tim Wright 3,228,425 10p 8 May 2010 8 May 2017
Nigel Goldsmith 2,235,617 10p 8 May 2010 8 May 2017
Ann Hardy 2,298,117 10p 8 May 2010 8 May 2017
John Gregory 310,702 10p 8 May 2010 8 May 2017
Total 8,383,563

The simplest explanation is surely that the market is adapting to the dilution effect of the 80million new shares issued at 10p - and today is only the first day of the 3 tranches of the 80 million being released to the market - so I suspect a continuation of the fall until a new market is established.

Have got this on my watchlist and may dip my toe for a longer term SIPP type punt in or around the 10p mark - probably below.

could well be if the dilution was not for better things. As it is the dillution has taken the company well into profiablity and in its own right MLR has already stated that its results to March 31 st 2007b will beat market expectations.

For me the dilution is not the answer and its a tough nut to crack

given that the exercise price is 10p, then that would certainly be a logical level at which to buy.

Very logical indeed only the problem with that theory would be the bid falling to around 9p and I cant see that happening, can you?

But if it did I then think so many would top up that it would not stay there for long---so its still worth watching, which is what I am doing right now.